Swayamjeet Satapathy1, Bhagwant Rai Mittal1, Anil Bhansali2. 1. Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 2. Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Abstract
OBJECTIVE: Inoperable and metastatic pheochromocytomas and paragangliomas (PPGLs) present a therapeutic challenge with current treatment options being limited to radiolabelled meta-iodo-benzyl-guanidine (MIBG) and systemic chemotherapy. Peptide receptor radionuclide therapy (PRRT) seems to be a promising option for these patients with few studies reporting favourable response. This systematic review was conducted to evaluate the efficacy and safety of PRRT in patients with advanced PPGLs. METHODS: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in PubMed, Scopus and Embase were made using relevant keywords and articles up to May 2019 were included. Data on efficacy and toxicity were extracted from the individual articles, and pooled estimates were generated using meta-analysis. RESULTS: Twelve articles consisting of 201 patients with advanced PPGLs were included. Overall, treatment with PRRT achieved an objective response rate of 25% (95% CI: 19%-32%) and a disease control rate of 84% (95% CI: 77%-89%). Clinical and biochemical responses were seen in 61% and 64% of the patients, respectively. Among the PRRTs, similar tumour response rates were noted for 90 Y-yttrium- and 177 Lu-lutetium-based agents. Treatment-related adverse effects were minimal with grade 3/4 neutropenia, thrombocytopenia, lymphopenia and nephrotoxicity observed in 3%, 9%, 11% and 4% of the patients, respectively. Treatment discontinuation was noted in five out of 102 patients. CONCLUSIONS: Peptide receptor radionuclide therapy is a safe and efficacious treatment option for advanced PPGLs and may be considered a viable alternative to chemotherapy and I-131 MIBG.
OBJECTIVE: Inoperable and metastatic pheochromocytomas and paragangliomas (PPGLs) present a therapeutic challenge with current treatment options being limited to radiolabelled meta-iodo-benzyl-guanidine (MIBG) and systemic chemotherapy. Peptide receptor radionuclide therapy (PRRT) seems to be a promising option for these patients with few studies reporting favourable response. This systematic review was conducted to evaluate the efficacy and safety of PRRT in patients with advanced PPGLs. METHODS: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in PubMed, Scopus and Embase were made using relevant keywords and articles up to May 2019 were included. Data on efficacy and toxicity were extracted from the individual articles, and pooled estimates were generated using meta-analysis. RESULTS: Twelve articles consisting of 201 patients with advanced PPGLs were included. Overall, treatment with PRRT achieved an objective response rate of 25% (95% CI: 19%-32%) and a disease control rate of 84% (95% CI: 77%-89%). Clinical and biochemical responses were seen in 61% and 64% of the patients, respectively. Among the PRRTs, similar tumour response rates were noted for 90 Y-yttrium- and 177 Lu-lutetium-based agents. Treatment-related adverse effects were minimal with grade 3/4 neutropenia, thrombocytopenia, lymphopenia and nephrotoxicity observed in 3%, 9%, 11% and 4% of the patients, respectively. Treatment discontinuation was noted in five out of 102 patients. CONCLUSIONS: Peptide receptor radionuclide therapy is a safe and efficacious treatment option for advanced PPGLs and may be considered a viable alternative to chemotherapy and I-131 MIBG.
Authors: Edward P Lin; Bennett B Chin; Lauren Fishbein; Toshio Moritani; Simone P Montoya; Shehanaz Ellika; Shawn Newlands Journal: Radiol Imaging Cancer Date: 2022-05
Authors: Jorge A Carrasquillo; Clara C Chen; Abhishek Jha; Karel Pacak; Daniel A Pryma; Frank I Lin Journal: J Nucl Med Date: 2021-09-01 Impact factor: 10.057
Authors: S Severi; A Bongiovanni; M Ferrara; S Nicolini; F Di Mauro; M Sansovini; I Lolli; E Tardelli; C Cittanti; V Di Iorio; E Mezzenga; E Scarpi; T Ibrahim; G Paganelli; S Zovato Journal: ESMO Open Date: 2021-06-14
Authors: Neeta Pandit-Taskar; Karel Pacak; Abhishek Jha; David Taïeb; Jorge A Carrasquillo; Daniel A Pryma; Mayank Patel; Corina Millo; Wouter W de Herder; Jaydira Del Rivero; Joakim Crona; Barry L Shulkin; Irene Virgolini; Alice P Chen; Bhagwant R Mittal; Sandip Basu; Joseph S Dillon; Thomas A Hope; Carina Mari Aparici; Andrei H Iagaru; Rodney J Hicks; Anca M Avram; Jonathan R Strosberg; Ali Cahid Civelek; Frank I Lin Journal: Clin Cancer Res Date: 2021-03-08 Impact factor: 13.801
Authors: Franz Sesti; Tiziana Feola; Giulia Puliani; Roberta Centello; Valentina Di Vito; Oreste Bagni; Andrea Lenzi; Andrea M Isidori; Vito Cantisani; Antongiulio Faggiano; Elisa Giannetta Journal: Front Oncol Date: 2021-06-17 Impact factor: 6.244